Clinical Trial Results:
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind,
Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment
due to Alzheimer’s Disease or With Mild Alzheimer’s Disease Dementia to Evaluate the
Safety of Continued Dosing in Subjects with Asymptomatic Amyloid-Related Imaging
Abnormalities
Summary
|
|
EudraCT number |
2018-002102-31 |
Trial protocol |
GB FR ES IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Jan 2021
|
First version publication date |
21 Jan 2021
|
Other versions |
|
Summary report(s) |
EudraCT Results Justification |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.